【摘要】 目的:了解利培酮治疗儿童期首发精神分裂症患者的疗效及安全性。 方法:对40例年龄<14岁患儿以利培酮治疗8周,以简明精神病评定量表(BPRS)评定疗效,以副反应量表(TESS)及实验室监测评价安全性。 结果:利培酮平均治疗剂量为(2.84±O.71)mg/d,总有效率为87.5％,不良反应主要为锥体外系反应。 结论:对儿童期首发精神分裂症,利培酮疗效较好,安全性高。更多还原

【Abstract】 Objective:To study the efficacy and safety of risperidone in treatment of childhood patients with first-episode schizophrenia. Method:40 outpatients with schizophrenia (age< 14 years) were treated with risperidone for 8 weeks.The efficacy was evaluated with the brief psychiatric rating scale (BPRS) .The safety was evaluated with the treatment emergent symptom scale (TESS) and the laboratory testing. Results: The average therapeutic dosage of risperidone was (2.84 ±0.71)mg/d,the total efficacious rate was 87.5% .The main side effect was slight EPS. Conclusion: It suggested that risperidone is an effective and safe antipsychotic in the treatment of childhood patients with schizophrenia.更多还原